Abstracts Archive - Page 2290 of 2425 - ACR Meeting Abstracts

Abstract Number: 1994 • 2012 ACR/ARHP Annual Meeting
The Influence of Percentage Body Fat On Bone Mineral Density in Thin Patients
Andrew Blanshard¹ and Marwan Bukhari², ¹Department of Rheumatology, Lancaster University, Lancaster, United Kingdom, ²Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Low Body Mass Index (BMI) is associated with low Bone Mineral Density (BMD) and subsequent risk of fragility fracture. Percentage body fat (%BF), which…
Abstract Number: 1995 • 2012 ACR/ARHP Annual Meeting
What Are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs?
Nicole C. Wright¹, Ana Oliveira², Amy H. Warriner³, Jeffrey R. Curtis², Neil Binkley⁴, Steven R. Cummings⁵, Marc C. Hochberg⁶, Andrea LaCroix⁷, E. Michael Lewiecki⁸, John T. Schousboe⁹, Daniel H. Solomon¹⁰, Robert B. Wallace¹¹ and Kenneth G. Saag¹², ¹Epidemiology, The University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ⁴University of Wisconsin, Madison, WI, ⁵San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA, ⁶Department of Medicine, University of Maryland, Baltimore, MD, ⁷Department of Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁸New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁹Department of Rheumatology, Park Nicollet Health Services, Minneapolis, MN, ¹⁰Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ¹¹Public Health, University of Iowa, Iowa City, IA, ¹²Div Clinical Immun & Rheum, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Pragmatic clinical trials (PCTs) allow for study of real world patients using efficient study designs, facilitating comparative effectiveness research in resource constrained settings. Although…
Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Marlies C. van der Goes¹, Johannes W.G. Jacobs¹, Maud S. Jurgens¹, Marije F. Bakker¹, Maaike J. van der Veen², Jacobine H. van der Werf³, Paco M.J. Welsing¹ and Johannes W.J. Bijlsma¹, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, St. Jansdal hospital, Harderwijk, Netherlands, ³Rheumatology, Diakonessenhuis, Utrecht, Netherlands
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…
Abstract Number: 1997 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Michael A. Bolognese¹, Edward Czerwinski², Henry G. Bone³, Sydney Bonnick⁴, Neil Binkley⁵, Alfred Moffett Jr.⁶, Suresh Siddhanti⁷, Irene Ferreira⁸, Prayashi Ghelani⁹, Rachel Wagman⁷, Jesse W. Hall⁷ and Chris Recknor¹⁰, ¹Bethesda Health Research Center, Bethesda, MD, ²Krakow Medical Center, Krakow, Poland, ³Michigan Bone and Mineral Clinic, Detroit, MI, ⁴Clinical Research Center of North Texas, Denton, TX, ⁵University of Wisconsin, Madison, WI, ⁶OB-GYN Associates of Mid Florida, PA, Leesburg, FL, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Amgen Inc., Cambridge, United Kingdom, ⁹Ovatech Solutions, London, United Kingdom, ¹⁰United Osteoporosis Centers, Gainesville, GA
Background/Purpose: Denosumab, a fully human monoclonal antibody that specifically targets RANKL to inhibit osteoclast formation, function, and survival, reduces risk for vertebral, non-vertebral, and hip…
Abstract Number: 1998 • 2012 ACR/ARHP Annual Meeting
Relationship Between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment
Michael A. Bolognese¹, Paul D. Miller², Jean-Yves Reginster³, Nathalie Franchimont⁴, Gerolamo Bianchi⁵, Roland Chapurlat⁶, Federico G. Hawkins⁷, David L. Kendler⁸, Beatriz Oliveri⁹, Jose R. Zanchetta¹⁰, Nadia Daizadeh⁴, Andrea Wang⁴, Rachel B. Wagman⁴ and Socrates Papapoulos¹¹, ¹Bethesda Health Research Center, Bethesda, MD, ²University of Colorado Health Sciences Center and Colorado Center for Bone Research, Lakewood, CO, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁴Amgen Inc., Thousand Oaks, CA, ⁵LELICOMAR - Div Reumatologia, Azienda Sanitaria Genovese, Genoa, Italy, ⁶Hôpital Edouard Herriot, Lyon, France, ⁷Hospital Universitario, Madrid, Spain, ⁸University of British Columbia, Vancouver, BC, Canada, ⁹Laboratorio Enfermedades Metabólicas Oseas, Hospital de Clínicas, INIGEM UBA-CONICET, Buenos Aires, Argentina, ¹⁰Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: During the first 3 years of denosumab treatment in FREEDOM, there were continued increases in bone mineral density (BMD) and a robust reduction in…
Abstract Number: 1999 • 2012 ACR/ARHP Annual Meeting
Immunogenicity and Safety of Two Doses of Influenza A H1N1⁄2009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old
Guilherme Trudes¹, Nadia E. Aikawa², Lucia M. Campos³, Rosa M.R. Pereira⁴, Julio C. B. Moraes⁵, Ana Cristina Ribeiro⁶, Joao Miraglia⁷, Maria do Carmo S. Timenetsky⁸, Eloisa Bonfa⁴ and Clovis Artur Silva⁹, ¹Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology, University of São Paulo, Sao Paulo, Brazil, ³Pediatric Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Rheumatology Divison, University of Sao Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Instituto Butantan, Fundação Butantan, São Paulo, Brazil, ⁸Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In 2010 the Advisory Committee on Immunization Practices from the CDC recommended that all children should receive the trivalent seasonal influenza vaccine containing the…
Abstract Number: 1959 • 2012 ACR/ARHP Annual Meeting
Low Fracture Incidence Is Maintained in Postmenopausal Women ≥75 Years with Osteoporosis with Long-Term Denosumab Treatment
Socrates Papapoulos¹, Michael McClung², Nathalie Franchimont³, Jonathan D. Adachi⁴, Henry G. Bone⁵, Claude-Laurent Benhamou⁶, Jordi Farrerons⁷, JC Gallagher⁸, Johan Halse⁹, Kurt Lippuner¹⁰, Salvatore Minisola¹¹, Ove Törring¹², Nadia Daizadeh³, Andrea Wang³, Rachel B. Wagman³ and Steven Boonen¹³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Oregon Osteoporosis Center, Portland, OR, ³Amgen Inc., Thousand Oaks, CA, ⁴St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Michigan Bone and Mineral Clinic, Detroit, MI, ⁶Centre Hospitalier Régional d'Orléans, Orleans, France, ⁷Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁸Creighton University Medical Center, Omaha, NE, ⁹Osteoporoseklinikken, Oslo, Norway, ¹⁰Bern University Hospital, Bern, Switzerland, ¹¹Sapienza, Università di Roma, Rome, Italy, ¹²Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, ¹³Leuven University, Leuven, Belgium
Background/Purpose: In the pivotal fracture trial, FREEDOM, denosumab increased bone mineral density (BMD) and reduced the incidence of new vertebral, nonvertebral, and hip fractures in…
Abstract Number: 1960 • 2012 ACR/ARHP Annual Meeting
Initiation of Tumor Necrosis Factor Alpha (TNFα) Antagonists and Risk of Fractures in Patients with Selected Rheumatic and Autoimmune Diseases
Vivian K. Kawai¹, Carlos Grijalva², Patrick Arbogast², Jeffrey R. Curtis³, Daniel H. Solomon⁴, Elizabeth S. Delzell⁵, Lang Chen⁶, Lisa Herrinton⁷, Liyan Liu⁷, Edward F. Mitchell Jr.², C. Michael Stein⁸ and Marie Griffin², ¹Vanderbilt University, Nashville, TN, ²Preventive Medicine, Vanderbilt University, Nashville, TN, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Division of Research, Kaiser Permanente, Oakland, CA, ⁸School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN
Initiation of Tumor Necrosis Factor Alpha (TNFα) antagonists and risk of fractures in patients with rheumatoid arthritis (RA)Background/Purpose: Inflammation mediates bone resorption, in part through…
Abstract Number: 1961 • 2012 ACR/ARHP Annual Meeting
In Postmenopausal Women with Osteoporosis, Denosumab Significantly Improved Trabecular Bone Score (TBS), an Index of Trabecular Microarchitecture
Michael McClung¹, Kurt Lippuner², Maria Luisa Brandi³, Jean-Marc Kaufman⁴, Jose R. Zanchetta⁵, Marc-Antoine Krieg⁶, Henry G. Bone⁷, Roland Chapurlat⁸, Didier Hans⁶, Andrea Wang⁹, Jang Yun⁹, Carol Zapalowski⁹ and Cesar Libanati⁹, ¹Oregon Osteoporosis Center, Portland, OR, ²University of Berne, Berne, Switzerland, ³University of Florence, Florence, Italy, ⁴University Hospital of Ghent, Ghent, Belgium, ⁵Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, ⁶Center of Bone Diseases, Lausanne University Hospital, Lausanne, Switzerland, ⁷Michigan Bone and Mineral Clinic, Detroit, MI, ⁸Hôpital Edouard Herriot, Lyon, France, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: The trabecular bone score (TBS), a novel gray-level texture index determined from lumbar spine DXA scans, correlates with 3D parameters of trabecular bone microarchitecture…
Abstract Number: 1962 • 2012 ACR/ARHP Annual Meeting
The Specific Role of Glutaredoxin2 Isoform b (Glrx2b) in RANKL-Induced Osteoclastogenesis Through Activation of the p38-MAPK Signaling Pathway
Chang-Hoon Lee¹, Wan-Hee Yoo², Jin-Jung Choi³, Myong-Joo Hong⁴, Ji-Min Kim⁵ and Jeong-Tae Yeon⁶, ¹Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, ²Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ³Internal Medicine, CHA University Hospital, Seongnam, South Korea, ⁴Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, ⁶Department of anatomy, school of medicine, Wonkwang university, Iksan, Chonbuk, South Korea
Background/Purpose: Recently, reactive oxygen species (ROS) and antioxidant enzymes were shown to be closely associated with RANKL-mediated osteoclast differentiation. Although glutaredoxin2 (Glrx2) plays a role…
Abstract Number: 1963 • 2012 ACR/ARHP Annual Meeting
Fracture Sites, Frequencies and Causes in 9,720 Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Cohort Study
Kensuke Ochi¹, Takefumi Furuya², Eisuke Inoue³, Katsunori Ikari⁴, Atsuo Taniguchi³, Shigeki Momohara⁴ and Hisashi Yamanaka², ¹Department of Orthopaedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Although rheumatoid arthritis (RA) is a risk factor for osteoporosis and fracture, limited data exist in the literature concerning fracture site and frequency in…
Abstract Number: 1964 • 2012 ACR/ARHP Annual Meeting
Rolofylline, an Adenosine A1R Antagonist, Acts As an Inverse Agonist to Inhibit Osteoclast Differentiation
Wenjie He¹ and Bruce N. Cronstein², ¹Dept of Med, Div of Rheum, NYU, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Previous work from our laboratory has uncovered a critical role of adenosine A1 receptor (A1R) in osteoclast formation both in vivo and in vitro.…
Abstract Number: 1965 • 2012 ACR/ARHP Annual Meeting
Adenosine Regulates Bone Metabolism Via A₁, A_2A and A_2B Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma
Wenjie He¹, Amitabha Mazumder² and Bruce N. Cronstein³, ¹Dept of Med, Div of Rheum, NYU, New York, NY, ²NYU Cancer Center, New York, NY, ³Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Multiple myeloma is a haematologic malignancy that is characterized by osteolytic bone lesions, wherein coupled bone remodeling is disrupted with increased osteoclast activation and…
Abstract Number: 1966 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Bazedoxifene Compared with Raloxifene in the Treatment of Postmenopausal Osteoporotic Women
Mickaël Hiligsmann¹, Wafa Ben Sedrine¹ and J.-Y. Reginster², ¹Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium, ²Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
Background/Purpose: Bazedoxifene is a novel selective estrogen receptor modulator (SERM) in development for the prevention and treatment of osteoporosis. In addition to the therapeutic value…
Abstract Number: 1967 • 2012 ACR/ARHP Annual Meeting
Hypophosphatemic Osteomalacia Induced by Tenofovir in Patients with Human Immunodeficiency Virus Infection
Beatriz Tejera¹, Lourdes Mateo-Soria², Susana Holgado³, Luisa Mariñoso⁴, Ricard Pérez⁵, Anna Bonjoch⁶, Melania Martínez-Morillo⁷, Dolors Grados³ and Alejandro Olivé³, ¹Rheumatology, University Hospital of Canary Islands, Santa Cruz de Tenerife, Spain, ²Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁴Pathology, Hospital del Mar, Barcelona, Spain, ⁵Radiology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁶HIV Unit, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Background/Purpose: treatment of human immunodeficiency virus (HIV) infection has dramatically changed survival prognosis of these patients.New drugs included in antiretroviral therapy are much more effective. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].